Abstract
Since 1996 and the introduction of the highly active antiretroviral therapy (HAART), we observe an increasing life expectancy in persons living with HIV (PLHIV) worldwide with a changing in death profile causes. Concerning the HIV infection, the World Health Organization (WHO) recommends the use of HAART. However, some disparities exist between countries, because of treatment access and local recommendations. The WHO recommends to start HAART when CD4 lymphocyte count is under 500/mm3. No specific references exist for the cancer treatments in PLHIV, while this is a fragile population with morbidities requiring more attention.
In this chapter, we will develop malignancies and HIV treatment references in high-income countries (the United States, Europe, Australia) and then on how to apply them in low-middle income countries (LMICs), to help physicians to improve patient care.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
GBD (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–171
Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C et al (2003) Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21(18):3447–3453
Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM et al (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20(12):1645–1654
Spano J-P, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D (2008) AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 26(29):4834–4842
Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK et al (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):753–762
Adebamowo CA, Casper C, Bhatia K, Mbulaiteye SM, Sasco AJ, Phipps W et al (2014) Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low- and middle-income countries in Africa. J Acquir Immune Defic Syndr 67 Suppl 1:S17–S26
Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC et al (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148(10):728–736
Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA et al (2009) HIV infection and the risk of cancers with and without a known infectious cause. AIDS 23(17):2337–2345
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach [Internet] (2013) World Health Organization, Geneva [cited 2015 Feb 22]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK195400/
Hoen B, Bonnet F, Delaugerre C, Delobel P, Goujard C, L’Hénaff M et al (2014) French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. J Int AIDS Soc 17:19034
Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P et al (2014) Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS 28(8):1181–1191
Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C et al (2008) Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 22(2):301–306
Writing Committee for the CASCADE Collaboration (2011) Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 171(17):1560–1569
HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JAC, Sabin C et al (2011) When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 154(8):509–515
Morlat P. Prise en charge médicale des personnes vivant avec le VIH, Rapport 2013
Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR et al (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375(9731):2092–2098
Bruyand M, Thiébaut R, Lawson-Ayayi S, Joly P, Sasco AJ, Mercié P et al (2009) Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 49(7):1109–1116
Borges AH, Dubrow R, Silverberg MJ (2014) Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS 9(1):34–40
Chiao EY, Dezube BJ, Krown SE, Wachsman W, Brock MV, Giordano TP et al (2010) Time for oncologists to opt in for routine opt-out HIV testing? JAMA 304(3):334–339
Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenewerth AM et al (2014) Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol 32(22):2344–2350
Xicoy B, Miralles P, Morgades M, Rubio R, Valencia M-E, Ribera J-M (2013) Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin’s lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. Haematologica 98(8):e85–e86
La Ferla L, Pinzone MR, Nunnari G, Martellotta F, Lleshi A, Tirelli U et al (2013) Kaposi’ s sarcoma in HIV-positive patients: the state of art in the HAART-era. Eur Rev Med Pharmacol Sci 17(17):2354–2365
Ablanedo-Terrazas Y, Alvarado-De La Barrera C, Reyes-Terán G (2013) Towards a better understanding of Kaposi sarcoma-associated immune reconstitution inflammatory syndrome. AIDS 27(10):1667–1669
Gobert A, Mounier N, Lavole A, Poizot-Martin I, Spano J-P (2014) HIV-related malignancies: state of art. Bull Cancer 101(11):1020–1029
Goosby E (2014) PEPFAR’s commitment to country ownership and achieving an AIDS-free generation. Lancet Glob Health 2(1), e18
Vermund SH (2014) Massive benefits of antiretroviral therapy in Africa. J Infect Dis 209(4):483–485
April MD, Wood R, Berkowitz BK, Paltiel AD, Anglaret X, Losina E et al (2014) The survival benefits of antiretroviral therapy in South Africa. J Infect Dis 209(4):491–499
Orem J, Wabinga H (2009) The roles of national cancer research institutions in evolving a comprehensive cancer control program in a developing country: experience from Uganda. Oncology 77(5):272–280
Casper C (2011) The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 62:157–170
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Lassoued, D., Gobert, A., Spano, JP. (2015). Cancer and HIV Treatments. In: Droz, JP., Carme, B., Couppié, P., Nacher, M., Thiéblemont, C. (eds) Tropical Hemato-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18257-5_55
Download citation
DOI: https://doi.org/10.1007/978-3-319-18257-5_55
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18256-8
Online ISBN: 978-3-319-18257-5
eBook Packages: MedicineMedicine (R0)